Clinical trials: Antipsychotic
Healthy Controls
Intranasal Insulin and Olanzapine Study in Healthy Volunteers
Antipsychotic (AP) medications are considered to be the gold standard treatment for psychotic disorders including schizophrenia.
- Trial name
- INI/OLA (NCT03741478)
- Testing
- OLANZapine 2.5 MG, Insulin Lispro 100 UNT/ML, Saline
- Where
- 2 sites in Canada
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Conduct Disorder, fMRI
Effects of Atypical Antipsychotics on Brain Function in Children and Teens With Conduct Disorders
Background: Some children and teenagers have conditions known as conduct disorders. They often have long-term chronic behavior problems, such as defiant behavior or violence.
- Trial name
- NCT01867398
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Adolescent Depression
Bone Mineral Content and Bone Metabolism in Adolescents on Antipsychotic Therapy
We hypothesize that antipsychotic induced hyperprolactinemia can decrease bone mineral accrual and decrease bone mineral content (BMC) in adolescents on antipsychotic therapy. Specifics Aims 1.
- Trial name
- NCT00399776
- Testing
- Bone Density Test
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Creighton University
Mental Disorders
Measurement of Cardiometabolic Risk in Antipsychotic-Treated Children
The proposed study aims to begin the multi-step process of establishing the reliability and validity of hepatic triglyceride content (HTGC) and carotid artery intima-media thickness (IMT) as biomarkers of cardiometablic risk in…
- Trial name
- NCT00894738
- Testing
- Testing (MRS, US, DEXA, blood tests)
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Schizophrenia, Psychotic Disorders
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up
Cognitive enhancement is a primary goal in treating individuals with schizophrenia. Cognitive deficits are already present at the first break of the illness, seem to remain stable during early phases and noticeably influence…
- Trial name
- PAFIP2_nc1Y (NCT02534363)
- Testing
- Aripiprazole, Quetiapine, Ziprasidone
- Where
- Spain
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Schizophrenia, Psychotic Disorders
Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis
The selection of antipsychotic in early stages of the illness is mainly determined by its clinical effectiveness. Second generation antipsychotics (SGAs) are the first line drug treatment for individuals suffering from…
- Trial name
- PAFIP2 (NCT02305823)
- Testing
- Aripiprazole, Quetiapine, Ziprasidone
- Where
- Spain
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Child Behavior Disorders
Safer Use of Antipsychotics in Youth
This study tests the effectiveness of an intervention treatment algorithm vs. usual care control in a practical clinical trial. Control arm providers will receive a standard medication alert in the electronic medical record (EMR)…
- Trial name
- SUAY (NCT03448575)
- Testing
- Control - Provider Medication Alert Only, Intervention - Alert + CAP Review AND Enhanced BH Access
- Where
- 4 sites in United States
- Volunteers
- 733 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Schizophrenia
Linear and Non-linear Analysis of EEG Changes in Schizophrenia After Atypical Antipsychotics Medication
The purpose of this study is to evaluate clinical meaning of EEG changes in antipsychotic-treated patients with schizophrenia.
- Trial name
- NCT00698295
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Schizophrenia
Antipsychotic Discontinuation in High-risk Subjects
Would be there any difference in dopamine synthesis between remitted clinical high risk subjects for psychosis and healthy control? What would happen to dopamine synthesis after antipsychotic discontinuation in clinical high risk…
- Trial name
- NCT01758887
- Where
- South Korea
- Volunteers
- healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Schizophrenia
The Effect of Hawthorn on Lipoprotein Cholesterol Ratio in Schizophrenics With Antipsychotics
Importance: The problems of side effects of metabolic disturbances in schizophrenic patients have been of worldwide concern for some time. Patients with dyslipidemia have an increased risk of cardiovascular diseases.
- Trial name
- NCT03663465
- Testing
- Hawthorn, SGAs
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Calo Psychiatric Center
Psychotic Disorders, Bipolar Disorder
Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI
The purpose of this study is to compare abdominal weight gain and fat distribution in people taking aripiprazole versus risperidone or quetiapine, to people not taking any of these antipsychotic medications.
- Conditions
- Psychotic Disorders, Bipolar Disorder, Metabolic Syndrome X
- Trial name
- CALM (NCT01739127)
- Testing
- Aripiprazole, Risperidone/Quetiapine
- Where
- Canada
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Schizophrenia, Psychotic Disorders
Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 1-year Follow-up
This study compares the efficacy and effectiveness of two of the second-generation antipsychotics (SGAs) most used in our society in the treatment of schizophrenia (Aripiprazole and Risperidone) and the investigators do within an…
- Trial name
- PAFIP3_1Y (NCT02532491)
- Testing
- Aripiprazole, Risperidone
- Where
- Spain
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Schizophrenia
Oculomotor and Spatial Cognition Deficits in Schizophrenia
DESCRIPTION: (Verbatim from the Applicant's Abstract) Abnormalities of eye movement control and spatial cognition are well-established deficits in schizophrenia.
- Trial name
- NCT00931996
- Testing
- Antipsychotic
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Schizophrenia, Psychotic Disorders
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 3-years Follow-up
Cognitive enhancement is a primary goal in treating individuals with schizophrenia. Cognitive deficits are already present at the first break of the illness, seem to remain stable during early phases and noticeably influence…
- Conditions
- Schizophrenia, Psychotic Disorders, Psychosis
- Trial name
- PAFIP3_nc3Y (NCT03883204)
- Testing
- Aripiprazole, Risperidone
- Where
- Spain
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Schizophrenia
Effects of Exposed to Antipsychotics Throughout Pregnancy on Infants Development: A Prospective Study
The primary aim of this prospective study is to evaluate the effect of antipsychotics on infant development especially neurobehavioral development which evaluated by the Bayley-III when mothers are treated with antipsychotics…
- Trial name
- NCT01479400
- Where
- China
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Central South University
Psychosis
Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis
The benefits and harms of antipsychotics are relatively well studied in adults. However, there is a lack of scientifically valid studies regarding the benefits and harms of antipsychotics in children and adolescents with…
- Trial name
- TEA (NCT01119014)
- Testing
- Aripiprazole, Quetiapine
- Where
- 9 sites in Denmark
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Anne Katrine Pagsberg
Schizophrenia, Hallucinations
Changes in Auditory Verbal Hallucination During Atypical Antipsychotic Treatment of Patients With Schizophrenia
The purpose of this study is to evaluate the changes in various aspects of auditory verbal hallucinations during 24-week antipsychotic treatment in naturalistic condition.
- Trial name
- NCT00328952
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Schizophrenia, Healthy
Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia
Cognitive impairment (such as challenges in thinking and memory) is a core aspect of schizophrenia (SCZ), contributing to disability and poor functional outcomes.
- Trial name
- NCT05748990
- Testing
- Intranasal insulin
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia
Standard Comprehensive Intervention to Treat First-episode Schizophrenia
Schizophrenia is not a curable but a treatable disease by antipsychotics. Kinds of atypical antipsychotics are widely used since 1990s' in China.
- Trial name
- NCT01057849
- Testing
- risperidone, olanzapine, Aripiprazole
- Where
- 6 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Peking University
Child Mental Disorders, Obesity
Healthy Bodies, Healthy Kids
The US prevalence of childhood-onset obesity and type 2 diabetes, both predictors of cardiovascular risk, have increased to epidemic proportions in recent decades.
- Conditions
- Child Mental Disorders, Obesity, Metabolic Syndrome
- Trial name
- NCT01222494
- Testing
- Behavioral Weight Loss, Diet and Exercise Education
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine